Ovarian Cancer

Ritu Salani, MD, discusses the role of ADCs in ovarian cancer and what the future of the post-IO setting in cervical cancer management may look like.

Laura J. Chambers, DO, discusses the role of genetic testing and PARP inhibitor maintenance therapy for patients with ovarian cancer.

Suvemcitug plus chemotherapy improved progression-free survival in platinum-resistant ovarian cancer.

Ceralasertib plus olaparib demonstrated clinical activity in platinum-sensitive, recurrent, high-grade serous ovarian cancer, regardless of HRD status.

IMNN-001 plus perioperative chemotherapy improved overall survival in newly diagnosed, advanced ovarian cancer.

Rezatapopt has displayed early signals of efficacy and tolerability in p53 Y220C-mutated solid tumors.

Don Dizon, MD, discusses updated findings from the BrUOG 354 trial and the future of immunotherapy for patients with ovarian cancers.

Here is your guide to the important regulatory decisions made by the FDA in June 2024.

The FDA has granted fast track designation to Radspherin for the treatment of patients with peritoneal metastases from ovarian cancer.

Vaidehi Mujumdar, MD, discusses several key trials that have helped shift the ovarian cancer treatment paradigm.

The FDA has approved a new drug application for Tepylute, a ready-to-dilute formulation to treat breast and ovarian cancers.

Mirvetuximab soravtansine generated PFS, OS, and ORR improvements in patients with ovarian cancer who required dose modifications in the MIRASOL trial.

Durvalumab/chemotherapy/bevacizumab, then durvalumab/bevacizumab/olaparib maintenance, sustained a PFS benefit in BRCA-unmutated advanced ovarian cancer.

The FDA placed partial clinical holds on trials evaluating azenosertib in advanced solid tumors, including ovarian cancer and uterine serous carcinoma.

Kimberly Cannavale, MPH, discusses findings from a retrospective study of comorbidity and remission outcomes in epithelial ovarian cancer.

Mirvetuximab soravtansine led to an ORR of 51.9% in heavily pretreated patients with FRα-positive, platinum-sensitive ovarian cancer.

Jean-Marc Classe, MD, PhD, discusses lymphadenectomy omission following cytoreductive surgery after chemotherapy in advanced epithelial ovarian cancer.

The addition of atezolizumab to bevacizumab and chemotherapy did not significantly improve overall survival or progression-free survival in patients with recurrent ovarian cancer.

The combination of nivolumab and ipilimumab improved responses as well as survival outcomes in patients with ovarian or gynecologic clear cell carcinomas.

The addition of lymphadenectomy to cytoreductive surgery did not improve progression-free or overall survival in advanced ovarian cancer.

In case you missed any, below is a recap of every OncLive On Air episode that aired in May 2024.

From barely escaping a life under communism in a Russia-occupied Latvia to overcoming a family health crisis, Robert F. Ozols, MD, PhD, knows a thing or two about beating the odds.

Treatment with CEE alone was associated with increased ovarian cancer incidence and mortality rates in postmenopausal women who had undergone hysterectomy.

Joyce F. Liu, MD, MPH, provides insights on WEE1 which has emerged as a potentially targetable pathway in high-grade serous ovarian cancer.

Timothy Yap, MBBS, PhD, FRCP, discusses encouraging data seen with the first-in-class PARP1 selective inhibitor saruparib in solid tumors and how the agent is being further investigated.